MANA Advisors’s PTC Therapeutics PTCT Stock Holding History

MANA Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,247	Closed	-$221K	–	342
2017 Q4	$221K	Buy	+13,247	New	+$224K	0.09%	329

Other funds holding PTCT

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MANA Advisors's PTCT Position: Q1 2018 in Review

MANA Advisors sold out of PTC Therapeutics (PTCT) in Q1 2018, closing a stake of 13,247 shares — an estimated $221K sold.

MANA Advisors first reported a position in PTCT in Q4 2017 and held it in 1 quarter. The position peaked at $221K in Q4 2017. 148 funds tracked by Wall St. Rank hold PTCT as of Q1 2018.

MANA Advisors reported no remaining PTC Therapeutics position as of Q1 2018 after selling out during the quarter.
MANA Advisors sold 13,247 PTC Therapeutics shares in Q1 2018, an estimated $221K.
MANA Advisors first reported a position in PTC Therapeutics in Q4 2017 and held it in 1 quarter.
MANA Advisors's PTC Therapeutics position peaked at $221K in Q4 2017.
148 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2018.

Based on MANA Advisors's 13F filing for Q1 2018, filed 15 May 2018.